A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

Inclusion Criteria * Males and females at least 18 years of age * Histologically- or cytologically- confirmed solid tumor (except melanoma) that is metastatic or unresectable * Advanced or metastatic cancer for which no standard therapy exists or that has progressed despite standard therapy * Acceptable organ and marrow function during the Screening Period as defined by the protocol. * Reliable venous access suitable for weekly study drug infusions * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures Exclusion Criteria * Pregnant or breast-feeding women * Have had chemotherapy or radiotherapy within 4 weeks prior to entering the study * Primary brain tumors or active brain metastases * Treatment with chronic immunosuppressants * Significant cardiovascular disease, severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration